USA - NASDAQ:AVR - US03675P1021 - Common Stock
The current stock price of AVR is 3.51 USD. In the past month the price decreased by -44.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.05 | 226.26B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.5 | 196.01B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.63 | 147.02B | ||
| SYK | STRYKER CORP | 27.3 | 137.45B | ||
| BDX | BECTON DICKINSON AND CO | 13.34 | 55.13B | ||
| IDXX | IDEXX LABORATORIES INC | 53.15 | 53.62B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.7 | 49.34B | ||
| RMD | RESMED INC | 24.87 | 35.93B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.47 | 32.42B | ||
| PODD | INSULET CORP | 72.97 | 23.47B | ||
| DXCM | DEXCOM INC | 32.35 | 23.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.01 | 17.65B |
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 136 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
ANTERIS TECHNOLOGIES GLOBAL
860 Blue Gentian Road, Suite 340
Eagan MINNESOTA US
Employees: 136
Phone: 16514930606
Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. The company is headquartered in Eagan, Minnesota and currently employs 136 full-time employees. The company went IPO on 2024-12-13. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
The current stock price of AVR is 3.51 USD. The price decreased by -1.68% in the last trading session.
AVR does not pay a dividend.
AVR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AVR stock is listed on the Nasdaq exchange.
ANTERIS TECHNOLOGIES GLOBAL (AVR) has a market capitalization of 126.57M USD. This makes AVR a Micro Cap stock.
ANTERIS TECHNOLOGIES GLOBAL (AVR) will report earnings on 2025-12-09.
ChartMill assigns a fundamental rating of 2 / 10 to AVR. The financial health of AVR is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months AVR reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS decreased by -65.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -210% | ||
| ROE | -350% | ||
| Debt/Equity | 0 |
8 analysts have analysed AVR and the average price target is 16.83 USD. This implies a price increase of 379.49% is expected in the next year compared to the current price of 3.51.
For the next year, analysts expect an EPS growth of 19.52% and a revenue growth 5.99% for AVR